Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Safety and Effectiveness of Two Doses of ABT-874 as Compared to Placebo in Subjects With Multiple Sclerosis (MS)

This study has been completed.
Information provided by (Responsible Party):
AbbVie ( AbbVie (prior sponsor, Abbott) ) Identifier:
First received: July 7, 2004
Last updated: January 2, 2013
Last verified: January 2013

The objective of the trial is to study the safety and effectiveness of ABT-874 administered weekly or every other week in patients with relapsing remitting and secondary progressive multiple sclerosis as compared to placebo. Effectiveness will be measured based on MRI scans done periodically throughout the study.

Condition Intervention Phase
Multiple Sclerosis
Drug: ABT-874/Human monoclonal antibody against IL-12
Drug: Placebo
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator)
Official Title: A 24-Week, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Dose Finding, Safety, Tolerability, and Efficacy Study of the Human Anti-IL-12 Antibody ABT-874 in Subjects With Multiple Sclerosis With a 24-Week Double-Blind, Active Extension Phase

Resource links provided by NLM:

Further study details as provided by AbbVie:

Primary Outcome Measures:
  • Comparison of the cumulative number of Gd enhanced (T1 weighted) lesions during the treatment phase [ Time Frame: 24 weeks ] [ Designated as safety issue: No ]
  • Safety and clinical laboratory parameters [ Time Frame: monthly ] [ Designated as safety issue: Yes ]
  • vital signs [ Time Frame: monthly ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:
  • Magnetic Resonance Imaging endpoints [ Time Frame: Screening ] [ Designated as safety issue: No ]
  • Magnetic Resonance Imaging endpoints [ Time Frame: Baseline (Week 0) ] [ Designated as safety issue: No ]
  • Magnetic Resonance Imaging endpoints [ Time Frame: Every 4 weeks after baseline through Week 24 ] [ Designated as safety issue: No ]
  • Magnetic Resonance Imaging endpoints [ Time Frame: Every 12 weeks from Week 26 to Week 120 ] [ Designated as safety issue: No ]
  • Magnetic Resonance Imaging endpoints [ Time Frame: Early Termination ] [ Designated as safety issue: No ]

Enrollment: 215
Study Start Date: April 2004
Study Completion Date: November 2006
Primary Completion Date: November 2006 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: ABT-874 200 mg weekly Drug: ABT-874/Human monoclonal antibody against IL-12
Placebo Comparator: Placebo Drug: Placebo
Experimental: ABT 874 QOW Drug: ABT-874/Human monoclonal antibody against IL-12

Detailed Description:

This study was done in subjects with relapsing remitting MS or secondary progressive MS with the objective of assessing the safety and efficacy of 200 mg of ABT-874 weekly or QOW versus placebo. There were 3 phases to the study, 24 week double blind followed by 24 weeks of an active extension, followed by 48 weeks of double blind active extension. The trial was discontinued by Abbott in Aug 2006.


Ages Eligible for Study:   18 Years to 60 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Age between 18 and 55 years
  • Diagnosis of active relapse within 12 months of screening.
  • At least one relapse within 12 months of screening.
  • Must be able to walk at least 65 feet with or without assistance
  • Off Copaxone or interferon therapy for two months prior to screening
  • Able and willing to learn to self-administer weekly injections, or have a designee who will administer study medication
  • Female participants must use contraceptives while on study drug

Exclusion Criteria:

  • Primary progressive multiple sclerosis (PPMS)
  • Immunosuppressive therapy (such as azathioprine, methotrexate (MTX), but excluding corticosteroids) within six months of randomization. Subjects with previous treatment with cyclophosphamide, total lymphoid irradiation, mitoxantrone, cladribine, or bone marrow transplantation, regardless of duration, will be excluded from participation in this study
  • Systemic corticosteroid therapy within four weeks prior to the first screening Magnetic Resonance Imaging (MRI)
  • Participation in any clinical study, whether or not it involves an investigational drug within three months prior to the screening visit
  • Use of any investigational drug with disease-modifying potential for the treatment of multiple sclerosis (MS) within six months of randomization (prior use of investigational agents for the symptomatic treatment of MS, e.g., 4-aminopyridine (4-AP), may be allowed following discussion with medical monitor
  • Concomitant statin use in doses exceeding the manufacturers' maximum recommended daily dosages for treatment of hypercholesterolemia or as part of an MS disease-modifying protocol
  • Infection or risk factors for severe infections
  • Excessive immunosuppression or other factors associated with it, including human immunodeficiency virus (HIV) infection
  • Severe, recurrent, or persistent infections [such as Hepatitis B or C, or borreliosis or recurrent urinary tract infection (UTI) (> 3 UTIs requiring antibiotic treatment per year) or recurrent pneumonia (> 2 pneumonias requiring antibiotic treatment per year) or infected decubitus ulcers]
  • Evidence of current inactive tuberculosis (TB) infection; recent exposure to mycobacterium tuberculosis (converters to a positive purified protein derivative [PPD]). Subjects with a positive PPD or a chest X-ray suggestive of prior TB infection will be excluded
  • Active tuberculosis disease
  • Active chronic Lyme disease
  • Active syphilis
  • Any other significant infection requiring hospitalization or intravenous (IV) antibiotics in the month prior to Screening; or
  • Infection requiring treatment with antibiotics in the two weeks prior to Screening.
  • Any of the following risk factors for development of malignancy:

    • History of lymphoma or leukemia
    • Cutaneous squamous-cell or basal cell carcinoma (EXCEPT if treated more that two years prior to Screening with evidence of recurrence or residual disease)
    • Other malignancy (EXCEPT if treated more than five years prior to Screening without evidence of recurrence or residual disease) or
    • Disease associated with an increased risk of malignancy (such as familial polyposis).
  • History of major immunologic reaction (such as serum sickness or anaphylactoid reaction) to an Immunoglobulin G (IgG) containing agent (such as intravenous (IV) gamma globulin, a fusion protein, or monoclonal antibody)
  • Confounders of the assessment of neurologic response including other diseases that produce chronic neurologic manifestations (such as amyotrophic lateral sclerosis, Guillain-Barre syndrome, Lyme disease, myasthenia gravis, etc.)
  • Prior exposure to anti-IL-12 antibodies
  • Confounders of safety assessment, such as an unstable medical condition not related to MS (including those requiring an adjustment of treatment in the four weeks prior to Screening)
  • Exacerbation of asthma requiring hospitalization in the ten years prior to Screening (subjects with asthma not requiring hospitalization should be discussed with the medical monitor prior to Screening)
  • Pregnant or lactating females
  • The following exclusionary laboratory values at screening or baseline:

    • Hemoglobin (Hgb) <10 g/dL in females or <12 g/dL in males;
    • White blood cell (WBC) count <3 x 109/L;
    • Platelet count <100 x 109/L
    • Serum aspartate transaminase (AST) or alanine transaminase (ALT) x 3 upper limits of normal (ULN);
    • Serum total bilirubin >/= 3 mg/dL (>/= 51 x mol/L)
    • Serum creatinine >1.6 mg/dL (> 141 x mol/L)
  • Subject has a recent history of substance abuse or psychiatric illness that could preclude compliance with the protocol
  • In the eight weeks prior to study drug administration, the subject has received a transfusion of any blood product, or has had 500 mL or more of blood removed by repetitive or one-time blood donation, plasmapheresis, or plasma exchange, or has lost 550 mL or more blood because of hemorrhage; or
  • For any reason, subject is considered by the investigator to be an unsuitable candidate to receive ABT-874.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00086671

  Show 44 Study Locations
Sponsors and Collaborators
AbbVie (prior sponsor, Abbott)
Study Chair: Martin Kaul, MD AbbVie
  More Information

No publications provided by AbbVie

Additional publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: AbbVie ( AbbVie (prior sponsor, Abbott) ) Identifier: NCT00086671     History of Changes
Other Study ID Numbers: M03-654
Study First Received: July 7, 2004
Last Updated: January 2, 2013
Health Authority: United States: Food and Drug Administration
Canada: Health Canada
Germany: Paul-Ehrlich-Institut
Netherlands: The Central Committee on Research Involving Human Subjects (CCMO)
United Kingdom: Medicines and Healthcare Products Regulatory Agency

Additional relevant MeSH terms:
Multiple Sclerosis
Autoimmune Diseases
Autoimmune Diseases of the Nervous System
Demyelinating Autoimmune Diseases, CNS
Demyelinating Diseases
Immune System Diseases
Nervous System Diseases
Pathologic Processes
Antibodies, Monoclonal
Immunologic Factors
Pharmacologic Actions
Physiological Effects of Drugs processed this record on November 25, 2014